HomeCompareELEV vs EPRT

ELEV vs EPRT: Dividend Comparison 2026

ELEV yields 547.95% · EPRT yields 3.97%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ELEV wins by $125545.48M in total portfolio value
10 years
ELEV
ELEV
● Live price
547.95%
Share price
$0.37
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$125545.55M
Annual income
$92,380,482,230.31
Full ELEV calculator →
EPRT
EPRT
● Live price
3.97%
Share price
$30.36
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$64.3K
Annual income
$13,170.85
Full EPRT calculator →

Portfolio growth — ELEV vs EPRT

📍 ELEV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodELEVEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ELEV + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ELEV pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ELEV
Annual income on $10K today (after 15% tax)
$46,575.34/yr
After 10yr DRIP, annual income (after tax)
$78,523,409,895.76/yr
EPRT
Annual income on $10K today (after 15% tax)
$337.37/yr
After 10yr DRIP, annual income (after tax)
$11,195.22/yr
At 15% tax rate, ELEV beats the other by $78,523,398,700.54/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ELEV + EPRT for your $10,000?

ELEV: 50%EPRT: 50%
100% EPRT50/50100% ELEV
Portfolio after 10yr
$62772.81M
Annual income
$46,190,247,700.58/yr
Blended yield
73.58%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

ELEV
Analyst Ratings
3
Buy
8
Hold
1
Sell
Consensus: Hold
Price Target
$9.00
+2365.8% upside vs current
Range: $8.00 — $10.00
Altman Z
-4.8
Piotroski
1/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+16.9% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ELEV buys
0
EPRT buys
0
No recent congressional trades found for ELEV or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricELEVEPRT
Forward yield547.95%3.97%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$125545.55M$64.3K
Annual income after 10y$92,380,482,230.31$13,170.85
Total dividends collected$122722.76M$38.7K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldBuy
Analyst price target$9.00$35.50

Year-by-year: ELEV vs EPRT ($10,000, DRIP)

YearELEV PortfolioELEV Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$65,495$54,794.52$11,212$512.01+$54.3KELEV
2$405,475$335,396.34$12,689$692.09+$392.8KELEV
3$2,374,450$1,940,591.70$14,521$944.30+$2.36MELEV
4$13,161,259$10,620,596.57$16,841$1,302.88+$13.14MELEV
5$69,099,868$55,017,321.36$19,841$1,821.64+$69.08MELEV
6$343,894,398$269,957,539.26$23,818$2,587.47+$343.87MELEV
7$1,623,590,885$1,255,623,879.22$29,230$3,744.65+$1623.56MELEV
8$7,277,465,834$5,540,223,587.11$36,816$5,540.38+$7277.43MELEV
9$30,995,389,120$23,208,500,677.65$47,806$8,413.17+$30995.34MELEV
10$125,545,548,589$92,380,482,230.31$64,324$13,170.85+$125545.48MELEV

ELEV vs EPRT: Complete Analysis 2026

ELEVStock

Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.

Full ELEV Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this ELEV vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ELEV vs SCHDELEV vs JEPIELEV vs OELEV vs KOELEV vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.